Study of Colchicine to Treat and Prevent Recurrent Pericarditis After Failure of Conventional Treatment.

Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The CORP 2 Trial: COlchicine for Recurrent Pericarditis.

The purpose of the study is to determine whether colchicine is safe and effective in treatment and prevention of recurrent pericarditis after failure of conventional treatment.

Colchicine is safe and effective in the management of recurrent pericarditis after failure of conventional treatment. Preliminary data (observational, non-randomized studies without a control group) have shown that the drug may be effective in treatment of the second and subsequent recurrence and the prevention of further recurrences.

Inclusion Criteria:

• Patients with the second and subsequent attack of recurrent pericarditis,
• Age≥ 18 years,
• Informed consent.

Exclusion Criteria:

• Suspected neoplastic, tuberculous, or purulent etiology,
• Known severe liver disease and/or elevated transaminases >1.5 times the upper limit of normality,
• serum creatinine>2.5 mg/dl,
• Serum CK over the upper limit of normality or Known myopathy,
• Known gastrointestinal or blood disease,
• Pregnant or lactating women or women not protected by a contraception method,
• Known hypersensibility to colchicine,
• Treatment with colchicine at the enrolment.